{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Angiogenesis > LinifanibCAS：796967-16-3
Molecular Formula：C21H18FN5O
Molecular Weight：375.41
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 796967-16-3 |
| Name | Linifanib |
| Molecular Formula | C21H18FN5O |
| Molecular Weight | 375.41 |
| Solubility | Soluble in DMSO ≥5mg/mL |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00012749 |
| SMILES | O=C(NC1=CC=C(C2=C3C(N)=NNC3=CC=C2)C=C1)NC4=C(C=CC(C)=C4)F |
| Target Point | PDGFR;VEGFR inhibitor |
| Passage | Angiogenesis; Protein Tyrosine Kinase/RTK |
| Background | It is a multi-target VEGF and PDGFR receptor family inhibitor. |
| Biological Activity | Linifanib (ABT-869) 是一种多靶点 VEGF 和 PDGFR 受体家族的抑制剂，抑制KDR，Flt-1，PDGFRβ和FLT3的 IC50 值分别为3，4，66，4 nM。[1] |
| IC50 | KDR:4nM;PDGFRβ:66nM;Flt-1:3nM;FLT3:4nM [1] |
| Data Literature Source | [1]. Albert DH，et al. Preclinical activity of ABT-869，a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther，2006，5(4)，995-1006. |
| Unit | Bottle |
| Specification | 5mg 10mg 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
